Stocklytics Platform
Asset logo for symbol MRK
Merck & Co
MRK65
$109.76arrow_drop_down0.38%-$0.42
S&P500
Asset logo for symbol MRK
MRK65

$109.76

arrow_drop_down0.38%

Income Statement (MRK)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
EBIT$6.26B$5.76B-$299.00M$6.18B-$4.67B
EBITDA$7.33B$6.74B$679.00M$7.19B-$3.76B
gross Profit$11.86B$12.23B$11.29B$11.69B$11.01B
NET Income$5.45B$4.76B-$1.22B$4.74B-$5.97B
total Revenue$16.15B$15.77B$14.63B$15.96B$15.03B

Balance Sheet (MRK)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
cash Equivalents---$8.60B$5.66B
net Debt$26.44B$28.64B$29.35B$26.21B$31.20B
stockholders Equity$43.58B$40.36B$37.58B$41.24B$38.69B
total Assets$112.63B$105.84B$106.67B$106.72B$104.46B
total Debt$37.78B-$36.26B$34.85B$36.91B
total Liabilities$68.98B$65.42B$69.04B$65.42B$65.72B

Cash Flow (MRK)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
financing Cash Flow$1.21B-$2.81B-$2.24B-$4.26B$3.75B
free Cash Flow$4.84B$2.22B-$743.00M$6.81B$2.73B
investing Cash Flow--$1.37B$53.00M-$334.00M-$11.44B
operating Cash Flow$5.63B$3.09B$246.00M$7.71B$3.70B

Merck & Co (MRK) Financials

Merck & Co Inc (MRK) is a global pharmaceutical company that specializes in the research, development, and production of prescription drugs. As of the latest financial report, the company has demonstrated strong financial performance. The income statement for Merck & Co Inc shows a consistent increase in total revenue over the past few years. In the most recent period, the company generated a substantial amount of total revenue, reflecting its market presence and successful product portfolio. Additionally, the gross profit for Merck & Co Inc has remained robust, indicating efficient cost management and a strong sales performance.
When analyzing the balance sheet of Merck & Co Inc, it is evident that the company has a solid financial position. The total assets of the company are substantial and indicate a strong foundation for growth and stability. The stockholders equity is also significant, indicating that the company is well-capitalized and has a positive net worth. Moreover, the company has a manageable level of total debt, suggesting a prudent approach to financial management. The cash equivalents of Merck & Co Inc are also notable, demonstrating the company's ability to meet short-term obligations and invest in growth opportunities.
In terms of cash flow, Merck & Co Inc has consistently displayed strong operating cash flow, which indicates the company's ability to generate cash from its core operations. The investing cash flow represents the amount of cash invested in long-term assets, such as property, plant, and equipment or acquisitions. Merck & Co Inc's investing cash flow has been significant, reflecting its commitment to research and development and expansion initiatives. The financing cash flow represents the cash flow generated or used by financing activities, including debt issuance, dividend payments, or share repurchases. Merck & Co Inc's financing cash flow has been stable, suggesting a prudent and disciplined approach to capital management.
One of the key financial metrics to assess the overall financial health of the company is EBIT (Earnings Before Interest and Taxes) and EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization). Merck & Co Inc has consistently reported a strong EBIT and EBITDA, indicating its ability to generate profits from its operations before accounting for interest, taxes, and depreciation. This implies that the company has a profitable business model and efficient cost management.
The net income from stockholders for Merck & Co Inc is a vital indicator of the company's profitability. The company has achieved a significant net income, reflecting its ability to generate profits for its shareholders. This demonstrates the company's successful execution of its business strategies and strong market position. Overall, Merck & Co Inc's financials reflect a well-managed and successful pharmaceutical company that continues to achieve consistent growth and profitability.
add Merck & Co  to watchlist

Keep an eye on Merck & Co

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media